Clinical Trial Details
| Trial ID: | L6037 |
| Source ID: | NCT02583438 |
| Associated Drug: | Saxagliptin (Bristol-Myers Squibb Company) |
| Title: | Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes|Obesity |
| Interventions: | DRUG: Saxagliptin (Bristol-Myers Squibb Company) |
| Outcome Measures: | Primary: gut microbiota, Change from Baseline Bacteroidetes abundances and composition of gut microbiota at 6 months | Secondary: The improvement of intestinal microflora imbalance, Bacteroidetes abundances and composition of gut microbiota (baseline, 4 weeks, 8 weeks and 12 weeks)|The change of inflammatory markers, The effect on plasma levels of inflammatory markers, such as IL-1B, IL-6 and TNF-α(baseline, 12 weeks), The change of inflammatory markers (baseline, 12 weeks) |
| Sponsor/Collaborators: | Sponsor: Beijing Chao Yang Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 100 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2015-10 |
| Completion Date: | 2018-01 |
| Results First Posted: | |
| Last Update Posted: | 2015-10-22 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT02583438 |
